Psycheceutical Bioscience Inc. (OTCMKTS:BWVI) Forms New Bioscience Medical Advisory Board

Psycheceutical Bioscience Inc. (OTCMKTS:BWVI) announced on October 18, 2022, about forming The Psycheceutical Bioscience Medical Advisory Board. It will comprise highly-respected healthcare providers with outstanding experience in advancing their respective fields of medicine.

Trading Data

On Tuesday, BWVI stock jumped 0.50% to $0.2030 with 11.57K shares, compared to volume of 47.87K shares. The stock moved within a range of $0.1930 – 0.2150 after opening trade at $0.2020.

Psycheceutical Bioscience, Inc. Announces Medical Advisory Board

These individuals will play an integral role, in order to guide the research and development efforts related to Psycheceutical’s next-generation psychedelic dosing technology. It is being developed to offer safer and more effective therapeutics.

The initial members of the board are – i) Julian E. Bailes, MD, Chairman of the Department of Neurosurgery, Co-Director of the Neurological Institute at NorthShore University Health System, and Clinical Professor of Neurosurgery at the University of Chicago Pritzker School of Medicine, ii) Thomas H. Cabell, MD, an American Board of Internal Medicine-certified cardiologist with the Centennial Heart Group at StoneCrest Medical Center, and iii) Tony L. Strickland M.S., Ph.D., FNAN, founder and CEO of Nexus Clinical Solutions and the Center for Postconcussion Syndrome and PTSD Treatment.

The Psycheceutical Bioscience Medical Advisory Board’s top agenda will be to support the company’s efforts to bring its innovative drug delivery technologies to market. Chad Harman, CEO of Psycheceutical, is thrilled to have Dr. Bailes, Dr. Cabell, and Dr. Strickland on board, and is confident their guidance and experience will benefit them immensely.

Key Quote

“Psycheceutical is at the forefront of innovation for the pharmaceutical adaptation of psychedelics, and I am proud to lead a board of well-respected and knowledgeable healthcare providers in helping Psycheceutical achieve its goal of continuously improving pharmaceutical delivery technologies and therapies for psychedelic medicine,” said Dr. Julian Bailes, Principal Medical Advisor of Psycheceutical.

Traders Corner

BWVI stock is trading below the 50-Day and 200-Day Moving averages of $0.20 and $0.22 respectively. Moreover, the stock is trading below the 20-Day moving average of $0.27.